BioMarin: Commercial Infrastructure Is The Hidden Growth Asset
BioMarin: Commercial Infrastructure Is The Hidden Growth Asset
BMRN - BioMarin Pharmaceutical Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$87.40
DETAILS
HIGH:
$120.00
LOW:
$50.00
MEDIAN:
$84.00
CONSENSUS:
$87.40
UPSIDE:
47.76%
Stock News
D.A. Davidson & CO. Acquires 36,293 Shares of BioMarin Pharmaceutical Inc. $BMRN
D.A. Davidson and CO. boosted its holdings in shares of BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) by 467.1% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 44,063 shares of the biotechnology company's stock after purchasing an additional 36,293 shares
FDA Accepts BMRN's sNDA Seeking Full Approval for Voxzogo
BioMarin's FDA filing for full Voxzogo approval in achondroplasia has been accepted, with a regulatory decision expected by Feb. 28, 2027.
U.S. Food and Drug Administration Accepts BioMarin's Supplemental New Drug Application for Full Approval of VOXZOGO® (vosoritide) for Children With Achondroplasia
Application based on long-term safety and efficacy data from three ongoing studies, including adult height and additional clinical outcomes beyond linear growth, including body proportionality and arm span evaluated over long-term follow-up FDA PDUFA target action date of Feb. 28, 2027 SAN RAFAEL, Calif., July 13, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that the U.S. Food and Drug Administration (FDA) has accepted the company's supplemental New Drug Application (sNDA) for VOXZOGO ® (vosoritide) for full approval in children with achondroplasia.
Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Value Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
BioMarin Announces New Three-Year VOXZOGO® (vosoritide) Data in Hypochondroplasia and BMN 333 Early Results at ENDO 2026
Data from an investigator-led study showed treatment with VOXZOGO resulted in sustained improvements in growth over three years in children with hypochondroplasia New Phase 1 results also presented for investigational BMN 333 support potential weekly dosing in children with achondroplasia SAN RAFAEL, Calif., June 16, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced new data from studies of VOXZOGO® (vosoritide) in children with hypochondroplasia and the investigational medicine BMN 333 in achondroplasia were presented at ENDO 2026, the Endocrine Society Annual Meeting, in Chicago.
BioMarin (BMRN) Up 0.2% Since Last Earnings Report: Can It Continue?
BioMarin (BMRN) reported earnings 30 days ago. What's next for the stock?
BioMarin's Voxzogo Meets Goal in Late-Stage Study for Hypochondroplasia
BMRN's shares rise after Voxzogo hits the main goal in a late-stage hypochondroplasia study, supporting planned FDA filings in 2026.
BioMarin Reveals Dwarfism Study Data, Stock Soars
BioMarin Pharmaceuticals Inc. (NASDAQ:BMRN) stock is trading higher on Thursday as the company is celebrating positive results from its Phase 3 CANOPY-HCH-3 study for VOXZOGO (vosoritide) in children with hypochondroplasia.
BioMarin's drug shows significant growth gains in children in late-stage trial
BioMarin Pharmaceutical said on Wednesday its treatment for a rare condition that leads to short stature helped boost growth in children, meeting the main goal of a late-stage study and sending shares up nearly 5% in extended trading.
BioMarin Announces Positive Phase 3 Pivotal Study Results for VOXZOGO® (vosoritide) in Children with Hypochondroplasia
Study met primary endpoint, exceeding expectations with a highly statistically significant improvement in annualized growth velocity (AGV, change from baseline) of 2.33 cm/yr compared to placebo at week 52, as well as statistically significant increases in standing height and height Z-score Study demonstrated statistically significant improvement in arm span at week 52 compared to placebo, a key measure linked to functional independence Safety findings consistent with the established profile in achondroplasia with no new safety signals identified Supplemental New Drug Application (sNDA) submission to U.S. Food and Drug Administration (FDA) planned for third quarter, followed by submissions to the European Medicines Agency (EMA) and other regional health authorities Full data to be presented at an upcoming medical meeting SAN RAFAEL, Calif., May 20, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that the Phase 3 CANOPY-HCH-3 study evaluating treatment with VOXZOGO ® (vosoritide) in children with hypochondroplasia met its primary endpoint, demonstrating a statistically significant increase in the change from baseline at week 52 in annualized growth velocity (AGV) compared to placebo (LS mean difference +2.33 cm/yr, p
BMRN Stock Down on Mixed Results From Rare Disease Therapy Study
BioMarin shares fall after BMN 401 meets a biomarker goal but misses a key radiographic endpoint in a late-stage ENPP1 deficiency study.
Here Are Tuesday’s Top Wall Street Analyst Research Calls: American Tower, Citigroup, CrowdStrike, Fortinet, Hanover Insurance, Jazz Pharmaceuticals, Stubhub, X-Energy, and More
Pre-Market Stock Futures: Futures are trading lower on Tuesday as the sell-off in technology stocks carried through to Monday and is headed down that road today. All of the major indices, except the Dow Jones Industrial Average, which closed 0.32% higher at 49,668, finished the day lower. The small-cap Russell 2000 was the big loser... Here Are Tuesday's Top Wall Street Analyst Research Calls: American Tower, Citigroup, CrowdStrike, Fortinet, Hanover Insurance, Jazz Pharmaceuticals, Stubhub, X-Energy, and More
BioMarin's genetic disease therapy shows mixed results in late-stage study
BioMarin Pharmaceutical said on Monday its experimental treatment for a rare genetic condition met one of the two main goals in a late-stage study.
BioMarin Provides Update on Phase 3 Trial for BMN 401 in Children Aged 1-12 With ENPP1 Deficiency
ENERGY 3 study met 1 of 2 co-primary endpoints in children with ENPP1 deficiency Treatment with BMN 401 led to statistically significant increases in plasma inorganic pyrophosphate (PPi) concentration, one of the study's co-primary endpoints; however, no improvement was observed in Radiographic Global Impression of Change (RGI-C) scores, the study's other co-primary endpoint and an important clinical measure of change in rickets severity Company is evaluating data to determine next steps SAN RAFAEL, Calif., May 18, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced results from the pivotal Phase 3 ENERGY 3 trial evaluating BMN 401 in children aged 1-12 with ENPP1 deficiency, a rare, serious and progressive genetic condition.
Here Are Monday’s Top Wall Street Analyst Research Calls: Dell Technologies, BioMarin Pharmaceutical, Disney, HubSpot, Klarna, Oklo, Pitney Bowes, Trade Desk, Wendy’s, and More
Pre-Market Stock Futures: Futures are trading mixed as we get set to start the new trading week, as reports indicate that President Trump declined Iran's counteroffer for peace. This comes after a remarkable Friday, when stocks roared to record highs, driven primarily by a stronger-than-expected April jobs report that eased economic concerns and by a... Here Are Monday's Top Wall Street Analyst Research Calls: Dell Technologies, BioMarin Pharmaceutical, Disney, HubSpot, Klarna, Oklo, Pitney Bowes, Trade Desk, Wendy's, and More
BioMarin: 'Strong Buy' On VOXZOGO Expansion And Amicus Acquisition
BioMarin Pharmaceutical remains a "Strong Buy," driven by pipeline progress, strategic acquisitions, and robust revenue guidance. BMRN's acquisition of Amicus Therapeutics adds GALAFOLD and POMBILITI + OPFOLDA, boosting 2026 revenue guidance to $3.825–$3.925 billion and targeting 20% YoY growth. VOXZOGO expansion into hypochondroplasia and ongoing clinical trials represent major catalysts, with topline Phase 3 data expected in Q2 2026.
BioMarin Q1 Earnings Miss, Sales Beat, '26 Revenue Guidance Raised
BMRN misses Q1 EPS estimates despite a revenue beat, as charges and higher costs weigh on profits, while new Amicus deal lifts the 2026 outlook.
BioMarin Pharmaceutical Inc. (BMRN) Q1 2026 Earnings Call Transcript
BioMarin Pharmaceutical Inc. (BMRN) Q1 2026 Earnings Call Transcript
Compared to Estimates, BioMarin (BMRN) Q1 Earnings: A Look at Key Metrics
Although the revenue and EPS for BioMarin (BMRN) give a sense of how its business performed in the quarter ended March 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Price Targets
BioMarin price target lowered to $62 from $66 at RBC Capital
$62.00
(was $58.79)
Luca Issi
·
RBC Capital
BioMarin price target lowered to $111 from $116 at Canaccord
$111.00
(was $54.10)
Canaccord Genuity
BioMarin price target lowered to $62 from $64 at Leerink
$62.00
(was $49.67)
Leerink Partners
BioMarin price target lowered to $50 from $55 at H.C. Wainwright
$50.00
(was $50.15)
H.C. Wainwright
BioMarin reinstated with a Neutral at Goldman Sachs
$69.00
(was $54.06)
Goldman Sachs
BioMarin price target raised to $120 from $110 at Evercore ISI
$120.00
(was $54.36)
Evercore ISI
BioMarin price target lowered to $82 from $94 at Bernstein
$82.00
(was $55.46)
William Pickering
·
Tudor Pickering
BioMarin resumed with an Overweight at Morgan Stanley
$120.00
(was $53.18)
Sean Laaman
·
Morgan Stanley
Jefferies Reiterates Buy Rating on BioMarin Pharmaceutical Inc. (BMRN): "data looks viable and is a positive sign"
$103.00
(was $59.86)
Akash Tewari
·
Jefferies
BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $105 at Barclays
$105.00
(was $59.74)
Eliana Merle
·
Barclays
BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $105 at Freedom Capital Markets
$105.00
(was $60.47)
Ilya Zubkov
·
Loop Capital Markets
BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $104 at Canaccord
$104.00
(was $60.26)
Whitney Ijem
·
Canaccord Genuity
BioMarin price target lowered to $95 from $98 at Oppenheimer
$95.00
(was $62.92)
Oppenheimer
BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $68 at Stifel
$68.00
(was $61.44)
Paul Matteis
·
Stifel Nicolaus
BioMarin price target raised to $75 from $70 at Wells Fargo
$75.00
(was $59.95)
Wells Fargo
BioMarin price target lowered to $84 from $122 at Piper Sandler
$84.00
(was $57.15)
Piper Sandler
BioMarin upgraded to Buy from Hold at Canaccord
$98.00
(was $54.59)
Canaccord Genuity
BioMarin price target raised to $100 from $80 at Truist
$100.00
(was $59.28)
Joon Lee
·
Truist Financial
BioMarin price target raised to $60 from $55 at H.C. Wainwright
$60.00
(was $61.15)
H.C. Wainwright
BioMarin downgraded to Market Perform from Outperform at Leerink
$60.00
(was $53.89)
Leerink Partners